Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for oral use. It is employed in the management of severe psoriasis and other disorders of keratinization, helping to normalize epidermal growth in adult patients.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Products are shipped in secure packaging to maintain stability during transit.

Neotigason (acitretin) is indicated for keratinization disorders and related dermatologic conditions. - Severe psoriasis: reduces scaling and plaque formation by normalizing keratinocyte differentiation. - Congenital ichthyosis: improves skin barrier function and decreases hyperkeratosis. - Other disorders of keratinization: helps control abnormal epidermal proliferation in conditions such as palmoplantar keratoderma.

Acitretin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry skin: increased xerosis and scaling. - Cheilitis: inflammation and cracking of the lips. - Elevated triglycerides: rise in serum lipid levels. - Hair loss: temporary alopecia. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Severe hyperlipidemia: marked increase in cholesterol or triglycerides. - Pseudotumor cerebri: symptoms of increased intracranial pressure. - Bone toxicity: premature epiphyseal closure in adolescents. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy with Neotigason, several safety considerations should be reviewed. - Pregnancy contraindication: drug is classified Category X and must not be used by pregnant women. - Contraception requirement: effective contraception is required for women of childbearing potential during treatment and for at least three years after discontinuation. - Liver function monitoring: baseline and periodic liver enzyme tests are advised. - Lipid profile monitoring: regular assessment of serum cholesterol and triglycerides is recommended. - Skeletal monitoring: avoid use in growing children due to risk of premature epiphyseal closure. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Acitretin can interact with several medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive toxicity leading to hypervitaminosis A. - Systemic corticosteroids: may exacerbate lipid abnormalities.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced effectiveness of hormonal contraception. - Antifungal azoles (e.g., ketoconazole): may increase acitretin plasma levels. - Lipid‑lowering agents (e.g., fibrates): require monitoring of lipid parameters. - Warfarin: potential alteration of anticoagulant effect.